Vertex Pharmaceuticals Incorporated (VX1.DE)
EUR 446.45
(-0.18%)
EUR 446.45
(-0.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 808.4 Million USD | 44.1% |
| 2022 | 561 Million USD | 0.77% |
| 2021 | 556.7 Million USD | -4.26% |
| 2020 | 581.47 Million USD | 0.71% |
| 2019 | 577.37 Million USD | 1.8% |
| 2018 | 567.16 Million USD | 0.58% |
| 2017 | 563.91 Million USD | -32.73% |
| 2016 | 838.24 Million USD | 2.15% |
| 2015 | 820.61 Million USD | -0.57% |
| 2014 | 825.29 Million USD | 87.17% |
| 2013 | 440.93 Million USD | -34.45% |
| 2012 | 672.63 Million USD | 68.16% |
| 2011 | 400 Million USD | -25.51% |
| 2010 | 536.99 Million USD | 249.07% |
| 2009 | 153.83 Million USD | -46.49% |
| 2008 | 287.5 Million USD | 1337.72% |
| 2007 | 19.99 Million USD | -83.84% |
| 2006 | 123.75 Million USD | -31.28% |
| 2005 | 180.09 Million USD | -46.24% |
| 2004 | 334.99 Million USD | -3.01% |
| 2003 | 345.38 Million USD | 5.26% |
| 2002 | 328.13 Million USD | 0.16% |
| 2001 | 327.6 Million USD | -6.32% |
| 2000 | 349.69 Million USD | 4825.21% |
| 1999 | 7.1 Million USD | -27.55% |
| 1998 | 9.8 Million USD | 16.67% |
| 1997 | 8.4 Million USD | -1.18% |
| 1996 | 8.5 Million USD | 21.43% |
| 1995 | 7 Million USD | 9.38% |
| 1994 | 6.4 Million USD | 6.67% |
| 1993 | 6 Million USD | 17.65% |
| 1992 | 5.1 Million USD | 54.55% |
| 1991 | 3.3 Million USD | 3.13% |
| 1990 | 3.2 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 933.4 Million USD | 29.41% |
| 2024 Q1 | 721.3 Million USD | -10.77% |
| 2023 Q4 | 808.4 Million USD | 8.55% |
| 2023 FY | 808.4 Million USD | 44.1% |
| 2023 Q1 | 789.2 Million USD | 40.68% |
| 2023 Q2 | 767.6 Million USD | -2.74% |
| 2023 Q3 | 744.7 Million USD | -2.98% |
| 2022 FY | 561 Million USD | 0.77% |
| 2022 Q1 | 544.2 Million USD | -2.25% |
| 2022 Q4 | 561 Million USD | 16.39% |
| 2022 Q2 | 531.6 Million USD | -2.32% |
| 2022 Q3 | 482 Million USD | -9.33% |
| 2021 Q1 | 572.85 Million USD | -1.48% |
| 2021 Q4 | 556.7 Million USD | -0.4% |
| 2021 FY | 556.7 Million USD | -4.26% |
| 2021 Q2 | 569.75 Million USD | -0.54% |
| 2021 Q3 | 558.93 Million USD | -1.9% |
| 2020 Q4 | 581.47 Million USD | -1.07% |
| 2020 Q1 | 572.91 Million USD | -0.77% |
| 2020 Q2 | 562.47 Million USD | -1.82% |
| 2020 Q3 | 587.77 Million USD | 4.5% |
| 2020 FY | 581.47 Million USD | 0.71% |
| 2019 Q4 | 577.37 Million USD | -0.22% |
| 2019 Q3 | 578.62 Million USD | -1.69% |
| 2019 Q2 | 588.57 Million USD | -1.26% |
| 2019 Q1 | 596.1 Million USD | 5.1% |
| 2019 FY | 577.37 Million USD | 1.8% |
| 2018 FY | 567.16 Million USD | 0.58% |
| 2018 Q1 | 567.49 Million USD | 0.64% |
| 2018 Q4 | 567.16 Million USD | 0.25% |
| 2018 Q3 | 565.74 Million USD | -0.77% |
| 2018 Q2 | 570.12 Million USD | 0.46% |
| 2017 FY | 563.91 Million USD | -32.73% |
| 2017 Q4 | 563.91 Million USD | 2.99% |
| 2017 Q3 | 547.54 Million USD | 4.19% |
| 2017 Q2 | 525.54 Million USD | 5.26% |
| 2017 Q1 | 499.28 Million USD | -40.44% |
| 2016 Q4 | 838.24 Million USD | 2.76% |
| 2016 Q3 | 815.74 Million USD | -0.65% |
| 2016 Q1 | 824.94 Million USD | 0.53% |
| 2016 Q2 | 821.09 Million USD | -0.47% |
| 2016 FY | 838.24 Million USD | 2.15% |
| 2015 Q4 | 820.61 Million USD | -0.04% |
| 2015 Q2 | 824.46 Million USD | -1.13% |
| 2015 Q3 | 820.98 Million USD | -0.42% |
| 2015 Q1 | 833.9 Million USD | 1.04% |
| 2015 FY | 820.61 Million USD | -0.57% |
| 2014 Q2 | 473.26 Million USD | -0.02% |
| 2014 FY | 825.29 Million USD | 87.17% |
| 2014 Q3 | 767.91 Million USD | 62.26% |
| 2014 Q1 | 473.36 Million USD | 7.35% |
| 2014 Q4 | 825.29 Million USD | 7.47% |
| 2013 Q4 | 440.93 Million USD | 12.32% |
| 2013 FY | 440.93 Million USD | -34.45% |
| 2013 Q1 | 716.82 Million USD | 6.57% |
| 2013 Q3 | 392.56 Million USD | 9.32% |
| 2013 Q2 | 359.1 Million USD | -49.9% |
| 2012 Q1 | 400 Million USD | 0.0% |
| 2012 FY | 672.63 Million USD | 68.16% |
| 2012 Q4 | 672.63 Million USD | 68.16% |
| 2012 Q3 | 400 Million USD | 0.0% |
| 2012 Q2 | 400 Million USD | 0.0% |
| 2011 FY | 400 Million USD | -25.51% |
| 2011 Q1 | 400 Million USD | -25.51% |
| 2011 Q2 | 400 Million USD | 0.0% |
| 2011 Q3 | 400 Million USD | 0.0% |
| 2011 Q4 | 400 Million USD | 0.0% |
| 2010 Q3 | 400 Million USD | 362.93% |
| 2010 Q4 | 536.99 Million USD | 34.25% |
| 2010 Q1 | 125.31 Million USD | -18.54% |
| 2010 Q2 | 86.4 Million USD | -31.05% |
| 2010 FY | 536.99 Million USD | 249.07% |
| 2009 Q1 | 287.5 Million USD | 0.0% |
| 2009 Q4 | 153.83 Million USD | 6.83% |
| 2009 Q3 | 144 Million USD | 0.0% |
| 2009 FY | 153.83 Million USD | -46.49% |
| 2009 Q2 | 144 Million USD | -49.91% |
| 2008 Q1 | 287.5 Million USD | 1337.72% |
| 2008 Q4 | 287.5 Million USD | 0.0% |
| 2008 Q3 | 287.5 Million USD | 0.0% |
| 2008 FY | 287.5 Million USD | 1337.72% |
| 2008 Q2 | 287.5 Million USD | 0.0% |
| 2007 Q2 | 62.09 Million USD | -4.79% |
| 2007 FY | 19.99 Million USD | -83.84% |
| 2007 Q1 | 65.22 Million USD | -47.29% |
| 2007 Q3 | 19.99 Million USD | -67.8% |
| 2007 Q4 | 19.99 Million USD | 0.0% |
| 2006 Q4 | 123.75 Million USD | 21.63% |
| 2006 FY | 123.75 Million USD | -31.28% |
| 2006 Q1 | 180.09 Million USD | 0.0% |
| 2006 Q2 | 180.09 Million USD | -0.0% |
| 2006 Q3 | 101.75 Million USD | -43.5% |
| 2005 Q1 | 334.99 Million USD | 0.0% |
| 2005 FY | 180.09 Million USD | -46.24% |
| 2005 Q3 | 294.54 Million USD | -12.07% |
| 2005 Q2 | 334.99 Million USD | 0.0% |
| 2005 Q4 | 180.09 Million USD | -38.86% |
| 2004 Q3 | 319.68 Million USD | -0.91% |
| 2004 Q2 | 322.61 Million USD | 2.41% |
| 2004 Q4 | 334.99 Million USD | 4.79% |
| 2004 FY | 334.99 Million USD | -3.01% |
| 2004 Q1 | 315.03 Million USD | -8.79% |
| 2003 FY | 345.38 Million USD | 5.26% |
| 2003 Q4 | 345.38 Million USD | 0.02% |
| 2003 Q3 | 345.33 Million USD | 1.34% |
| 2003 Q2 | 340.77 Million USD | 3.3% |
| 2003 Q1 | 329.89 Million USD | 0.54% |
| 2002 Q2 | 325.24 Million USD | -0.31% |
| 2002 Q1 | 326.25 Million USD | -0.41% |
| 2002 FY | 328.13 Million USD | 0.16% |
| 2002 Q4 | 328.13 Million USD | 1.19% |
| 2002 Q3 | 324.28 Million USD | -0.3% |
| 2001 FY | 327.6 Million USD | -6.32% |
| 2001 Q4 | 327.6 Million USD | -8.68% |
| 2001 Q3 | 358.74 Million USD | 2.9% |
| 2001 Q2 | 348.64 Million USD | -0.14% |
| 2001 Q1 | 349.15 Million USD | -0.15% |
| 2000 Q4 | 349.69 Million USD | -31.69% |
| 2000 FY | 349.69 Million USD | 4825.21% |
| 2000 Q1 | 181.42 Million USD | 2455.31% |
| 2000 Q2 | 180.82 Million USD | -0.33% |
| 2000 Q3 | 511.92 Million USD | 183.11% |
| 1999 Q4 | 7.1 Million USD | -8.97% |
| 1999 FY | 7.1 Million USD | -27.55% |
| 1999 Q1 | 9.1 Million USD | -7.14% |
| 1999 Q2 | 8.4 Million USD | -7.69% |
| 1999 Q3 | 7.8 Million USD | -7.14% |
| 1998 Q4 | 9.8 Million USD | -5.77% |
| 1998 Q1 | 8.7 Million USD | 3.57% |
| 1998 Q2 | 9.6 Million USD | 10.34% |
| 1998 Q3 | 10.4 Million USD | 8.33% |
| 1998 FY | 9.8 Million USD | 16.67% |
| 1997 FY | 8.4 Million USD | -1.18% |
| 1997 Q3 | 8.2 Million USD | 0.0% |
| 1997 Q1 | 8.1 Million USD | -4.71% |
| 1997 Q2 | 8.2 Million USD | 1.23% |
| 1997 Q4 | 8.4 Million USD | 2.44% |
| 1996 FY | 8.5 Million USD | 21.43% |
| 1996 Q4 | 8.5 Million USD | 23.19% |
| 1996 Q3 | 6.9 Million USD | 0.0% |
| 1996 Q2 | 6.9 Million USD | 6.15% |
| 1996 Q1 | 6.5 Million USD | -7.14% |
| 1995 Q2 | 6.9 Million USD | 4.55% |
| 1995 Q1 | 6.6 Million USD | 3.13% |
| 1995 Q4 | 7 Million USD | 2.94% |
| 1995 Q3 | 6.8 Million USD | -1.45% |
| 1995 FY | 7 Million USD | 9.38% |
| 1994 Q3 | 6.3 Million USD | 5.0% |
| 1994 FY | 6.4 Million USD | 6.67% |
| 1994 Q1 | 5.5 Million USD | -8.33% |
| 1994 Q2 | 6 Million USD | 9.09% |
| 1994 Q4 | 6.4 Million USD | 1.59% |
| 1993 Q1 | 5.3 Million USD | 3.92% |
| 1993 Q2 | 5.9 Million USD | 11.32% |
| 1993 FY | 6 Million USD | 17.65% |
| 1993 Q4 | 6 Million USD | 1.69% |
| 1993 Q3 | 5.9 Million USD | 0.0% |
| 1992 FY | 5.1 Million USD | 54.55% |
| 1992 Q4 | 5.1 Million USD | 2.0% |
| 1992 Q1 | 3.6 Million USD | 9.09% |
| 1992 Q2 | 4.4 Million USD | 22.22% |
| 1992 Q3 | 5 Million USD | 13.64% |
| 1991 Q4 | 3.3 Million USD | -5.71% |
| 1991 Q3 | 3.5 Million USD | 0.0% |
| 1991 FY | 3.3 Million USD | 3.13% |
| 1991 Q2 | 3.5 Million USD | 0.0% |
| 1990 FY | 3.2 Million USD | 0.0% |
| 1990 Q4 | 3.2 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BioNTech SE | 219.1 Million EUR | -268.964% |
| CureVac N.V. | 41.85 Million EUR | -1831.269% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | -17.193% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | -17.193% |
| BRAIN Biotech AG | 4.65 Million EUR | -17251.363% |
| Formycon AG | 29.48 Million EUR | -2641.64% |
| Heidelberg Pharma AG | 5.83 Million EUR | -13762.933% |
| Medigene AG | 2.95 Million EUR | -27303.39% |